New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2013
10:03 EDTTEVA, ACT, MYLGeneric drug makers fall after Wells analyst downgrades sector
A number of generic drug makers are losing ground after Wells Fargo analyst Michael Tong downgraded the sector to Market Weight from Overweight in a note to investors earlier today. After four years of outperformance, companies in the sector may have to exploit new catalysts in order to advance further, Tong believes. These new catalysts, however, carry more risks than previous drivers of the stock, the analyst contended. Upcoming catalysts for the sector include profitable international expansion, diversified brand portfolio, and biosimilars, Tong wrote. Investors should move out of generic drug stocks and buy the stocks of large drug companies, the analyst recommended. In the same note, Tong downgraded two specific generic drug makers. He dropped Teva (TEVA) to Market Perform from Outperform and lowered Actavis (ACT) to Market Perform from Outperform. Teva is taking longer than expected to implement its turnaround plan and may face increased competition to its Copaxone MS treatment, while Actavis' stock price has risen to the point where the shares accurately reflect the company's long-term outlook, Tong believes. In early trading, Teva fell 1% to $40.35, Actavis gave back 2% to $90, and Mylan (MYL) lost 1% to $30.15.
News For TEVA;ACT;MYL From The Last 14 Days
Check below for free stories on TEVA;ACT;MYL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 25, 2014
06:30 EDTMYLObama calls on Congress to end inversion deals, NY Times reports
Subscribe for More Information
06:11 EDTMYLMylan downgraded to Neutral from Buy at Citigroup
Subscribe for More Information
July 24, 2014
14:35 EDTMYLObama to call for elimination of tax inversion deals, NY Times says
President Obama will call on Congress today to eliminate the tax inversion loophole, according to The New York Times. Among the deals or possible transactions that involve inversion are Mylan's (MYL) acquisition of Abbott’s (ABT), Medtronic's acquisition of Covidien (COV)and Valeant's (VRX) proposed takeover of Alletgan (AGN)Reference Link
07:27 EDTTEVASome of Teva's biggest investors to vote against re-electing directors, WSJ says
Subscribe for More Information
06:45 EDTTEVATeva price target raised to $70 from $65 at Barclays
Subscribe for More Information
July 23, 2014
10:02 EDTMYL, TEVA, ACTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTMYL, TEVA, ACTDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
07:09 EDTMYLMylan wins restraining order against Apotex for generic version of GSK's Paxil
Subscribe for More Information
06:45 EDTMYLLawmakers divided on inversion deals, NY Times says
Subscribe for More Information
July 22, 2014
16:09 EDTACTActavis initiated with a Buy at Deutsche Bank
Subscribe for More Information
16:08 EDTTEVATeva initiated with a Buy at Deutsche Bank
Subscribe for More Information
16:08 EDTMYLMylan initiated with a Buy at Deutsche Bank
Target $67.
July 21, 2014
16:36 EDTACTActavis and Medicines360 announce FDA acceptance of Levosert NDA
Subscribe for More Information
08:11 EDTTEVAArena Pharma' subsidiary enters into agreement for Belviq with Teva subsidiary
Subscribe for More Information
08:01 EDTTEVATeva completes acquisition of Labrys
Subscribe for More Information
July 18, 2014
16:47 EDTMYLMarket ends week higher as earnings, M&A offset geopolitical tensions
Subscribe for More Information
12:51 EDTMYLKey GOP senator signals readiness for inversion deal, The Hill says
Subscribe for More Information
July 17, 2014
15:42 EDTACTDepomed says Actavis preliminarily enjoined from marketing generic Gralise
Subscribe for More Information
11:07 EDTMYLAcorda sues Mylan over plans to duplicate Ampyra MS drug, Bloomberg says
07:18 EDTMYLMylan wins motion to enjoin GlaxoSmithKline from production of generic product
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use